BJH - volume 13, issue 5, september 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
During the past European Hematology Association’s annual congress (EHA 2022), four oral sessions were devoted to clinical trials and recent advances in myeloma. These sessions covered newly diagnosed multiple myeloma (MM), antibody-based therapy in relapsed/refractory (RR) MM, BCMA-directed treatment in RRMM and biology and translational research. Below, we summarise the highlights from some of the studies that were presented in each of these sessions.
(BELG J HEMATOL 2022;13(5):219–23)
Read moreBJH - volume 13, issue 4, june 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (
(BELG J HEMATOL 2022;13(4):175–8)
Read moreBJH - volume 13, issue 3, may 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.
(BELG J HEMATOL 2022;13(3):137–40)
Read moreBJH - volume 13, issue 2, march 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this section of the BJH, we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.
(BELG J HEMATOL 2022;13(2):101–3)
Read moreBJH - 2022, issue SPECIAL, april 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In a first presentation of the BHS-GAM 2022 session dedicated to novel cellular therapies, Dr. Sophie Servais (CHU Liège, Belgium) shared the results of the first Belgian real-world experience of anti-CD19 CAR-T cells in patients with relapsed or refractory large B-cell lymphoma. Next Prof. Dr. Barbara De Moerloose (University Hospital Ghent, Belgium) shared her personal experience with tisagenlecleucel in the treatment of paediatric and young adults with acute lymphoblastic leukaemia (ALL). In a final presentation, Prof. Dr. Daan Dierickx (University Hospital Leuven, Belgium) discussed the potential of redirecting T-cells against the Epstein–Barr virus, mainly in patients with posttransplant lymphoproliferative disease.
Read moreBJH - 2022, issue SPECIAL, april 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
Although palliative care is often associated with end-of-life and death, its concept is much broader than that and should focus on providing relief from the symptoms and stress of any serious illness. In the Ethics session of the 2022 BHS GAM meeting, Prof. Dr. Thomas LeBlanc (Duke Cancer Institute, Durham, North Carolina, USA) discussed the unmet needs regarding advance care planning and specialist palliative care integration in haematology. In addition, he shared the results of a randomised trial of integrated palliative and oncology care for patients with acute myeloid leukaemia, demonstrating significant advances of palliative care for patients.
Read moreBJH - 2022, issue SPECIAL, april 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
The annual Pierre Stryckmans Memorial Lecture at this years’ BHS-GAM was presented by Prof. Dr. Bob Löwenberg (Erasmus University Medical Center, Rotterdam, The Netherlands), awarding him for his lifetime achievements in the diagnosis and treatment of acute myeloid leukaemia (AML).
Historically, intensive treatment for AML consists of induction chemotherapy, followed by post-remission consolidation therapy with chemotherapy and an autologous (auto-SCT) or allogeneic stem cell transplantation (allo-SCT) to eradicate potential residual cells.1 In order to improve on the treatment outcomes that can be achieved today, we need a deeper understanding of the molecular diversity of the disease and its functional consequences. Furthermore, we should aim for a further personalization of the treatment, tailored to the individual patient.
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
